PL3892631T3 - Białko fuzyjne do zastosowania w leczeniu choroby hvg - Google Patents

Białko fuzyjne do zastosowania w leczeniu choroby hvg

Info

Publication number
PL3892631T3
PL3892631T3 PL21158543.5T PL21158543T PL3892631T3 PL 3892631 T3 PL3892631 T3 PL 3892631T3 PL 21158543 T PL21158543 T PL 21158543T PL 3892631 T3 PL3892631 T3 PL 3892631T3
Authority
PL
Poland
Prior art keywords
treatment
fusion protein
hvg disease
hvg
disease
Prior art date
Application number
PL21158543.5T
Other languages
English (en)
Inventor
Elmar Jäckel
Fatih NOYAN
Michael Hust
Original Assignee
Medizinische Hochschule Hannover
Technische Universität Braunschweig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover, Technische Universität Braunschweig filed Critical Medizinische Hochschule Hannover
Publication of PL3892631T3 publication Critical patent/PL3892631T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL21158543.5T 2016-06-30 2017-06-22 Białko fuzyjne do zastosowania w leczeniu choroby hvg PL3892631T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16177208.2A EP3263595A1 (en) 2016-06-30 2016-06-30 Fusion protein for use in the treatment of hvg disease

Publications (1)

Publication Number Publication Date
PL3892631T3 true PL3892631T3 (pl) 2024-07-01

Family

ID=56321806

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21158543.5T PL3892631T3 (pl) 2016-06-30 2017-06-22 Białko fuzyjne do zastosowania w leczeniu choroby hvg
PL21158544.3T PL3865506T3 (pl) 2016-06-30 2017-06-22 Białko fuzyjne do zastosowania w leczeniu choroby hvg

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21158544.3T PL3865506T3 (pl) 2016-06-30 2017-06-22 Białko fuzyjne do zastosowania w leczeniu choroby hvg

Country Status (6)

Country Link
US (2) US11160831B2 (pl)
EP (5) EP3263595A1 (pl)
CN (2) CN109476726B (pl)
ES (2) ES2991327T3 (pl)
PL (2) PL3892631T3 (pl)
WO (1) WO2018001874A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3714944A1 (en) 2019-03-29 2020-09-30 Medizinische Hochschule Hannover Car for use in the treatment of hvg disease
EP3263595A1 (en) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
MX2019003462A (es) * 2016-09-28 2019-08-16 Gavish Galilee Bio Appl Ltd Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
KR102742220B1 (ko) 2017-09-19 2024-12-17 더 유니버시티 오브 브리티쉬 콜롬비아 항-hla-a2 항체 및 그 사용 방법
US11814432B2 (en) 2017-09-20 2023-11-14 The University Of British Columbia Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
PL3688155T3 (pl) 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
MX2020010808A (es) 2018-04-13 2021-03-02 Sangamo Therapeutics France Receptor de antigeno quimerico especifico para el receptor de interleucina-23.
US12227756B2 (en) * 2018-04-18 2025-02-18 Ucl Business Ltd Engineered regulatory T cell
WO2019241549A1 (en) * 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
BR112021006100A2 (pt) * 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
EP3733697A1 (en) 2019-04-30 2020-11-04 Medizinische Hochschule Hannover Artificial signalling molecule
JP2022533713A (ja) * 2019-05-21 2022-07-25 サンガモ セラピューティクス， インコーポレイテッド 調節性ｔ細胞における制御された導入遺伝子発現
GB201915384D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Vector
WO2021119489A1 (en) 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
CN111019906A (zh) * 2019-12-26 2020-04-17 华中科技大学同济医学院附属协和医院 治疗移植排斥反应的嵌合受体重组基因的构建方法及应用
CN111440246B (zh) * 2020-04-16 2022-03-18 成都仕康美生物科技有限公司 靶向HLA-B的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途
CN111393533B (zh) * 2020-04-16 2021-05-11 成都仕康美生物科技有限公司 靶向HLA-A的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途
US20230203108A1 (en) * 2020-05-28 2023-06-29 Chugai Seiyaku Kabushiki Kaisha Improved granzyme b variant
EP4058474B1 (en) 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
GB202013477D0 (en) * 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
EP4251202A4 (en) * 2020-11-30 2025-04-09 Merck Sharp & Dohme LLC ARGINASE-1 BINDING AGENT FOR INHIBITING ARGINASE-1 ACTIVITY
WO2022165419A1 (en) * 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
IL304857A (en) 2021-02-16 2023-10-01 A2 Biotherapeutics Inc Preparations and methods for treating HER2 POSITIVE cancer
CN117377691A (zh) * 2021-03-19 2024-01-09 葛兰素史密斯克莱知识产权发展有限公司 靶向密蛋白3的嵌合抗原受体和治疗癌症的方法
CN113563464B (zh) * 2021-08-01 2023-02-03 中国疾病预防控制中心性病艾滋病预防控制中心 人源化高中和活性抗新型冠状病毒单克隆抗体及应用
US20250017967A1 (en) 2021-12-17 2025-01-16 Quell Therapeutics Limited Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells
EP4496883A1 (en) 2022-03-22 2025-01-29 Quell Therapeutics Limited Methods and products for culturing t cells and uses thereof
US20250353889A1 (en) 2022-06-10 2025-11-20 Medizinische Hochschule Hannover Fusion protein for maintenance of regulatory t-cells
EP4289859A1 (en) 2022-06-10 2023-12-13 Medizinische Hochschule Hannover Fusion protein for maintenance of regulatory t-cells
WO2025038646A1 (en) * 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Cd70 car-t compositions and methods for cell-based therapy
US20260176598A1 (en) 2024-07-04 2026-06-25 Quell Therapeutics Limited Expression construct
EP4678187A1 (en) 2024-07-11 2026-01-14 Medizinische Hochschule Hannover Compound for use in the treatment of inflammatory bowel disease
WO2026064255A1 (en) * 2024-09-17 2026-03-26 The Trustees Of Columbia University In The City Of New York Chimeric antigen receptor (car) tregs against pan class i swine leukocyte antigen and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2126054T (pt) 2007-01-31 2016-10-12 Yeda Res & Dev Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias
EP2473523A2 (en) * 2009-08-31 2012-07-11 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
MX359411B (es) 2012-01-13 2018-09-27 Univ Wuerzburg J Maximilians Complementación funcional bipartita inducida por antígenos, dual.
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
DK3105335T3 (da) * 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
EP3263595A1 (en) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
CN110678190A (zh) * 2017-03-28 2020-01-10 宾夕法尼亚大学董事会 保护移植的组织免受排斥的方法

Also Published As

Publication number Publication date
US20190290691A1 (en) 2019-09-26
ES2991327T3 (es) 2024-12-03
EP3263595A1 (en) 2018-01-03
EP3478710B1 (en) 2021-06-02
ES2973087T3 (es) 2024-06-18
EP3478710A1 (en) 2019-05-08
EP3865506A1 (en) 2021-08-18
EP3892631B1 (en) 2023-12-13
US12466871B2 (en) 2025-11-11
US20220133796A1 (en) 2022-05-05
WO2018001874A1 (en) 2018-01-04
EP3865506B1 (en) 2024-08-21
PL3865506T3 (pl) 2025-01-07
US11160831B2 (en) 2021-11-02
EP4098660A1 (en) 2022-12-07
CN109476726A (zh) 2019-03-15
EP3892631A1 (en) 2021-10-13
CN116693691A (zh) 2023-09-05
CN109476726B (zh) 2023-04-18

Similar Documents

Publication Publication Date Title
PL3865506T3 (pl) Białko fuzyjne do zastosowania w leczeniu choroby hvg
IL284250A (en) Tau antibodies of human origin in Alzheimer's disease
ZA201806436B (en) Insecticidal proteins and methods for their use
PL3310805T3 (pl) Białka fuzyjne pd-1-cd28 i ich zastosowanie w medycynie
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
GB201904563D0 (en) Fusion protein and applications thereof
PL3377909T3 (pl) Laktoferyna do zastosowania w diagnozowaniu lub prognozowaniu choroby Alzheimera
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
ZA201902689B (en) Therapeutic protein
PL3423060T3 (pl) Imatynib do stosowania w leczeniu udaru mózgu
PT3413870T (pt) Igmesina para utilização no tratamento de doença de alzheimer
PL3675879T3 (pl) Cerebrolizyna do zastosowania w leczeniu cadasil
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
ZA201801788B (en) Lysobactin for use in the treatment of bovine mastitis
IL256880A (en) Combining proteins for the diagnosis of schizophrenia
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
GB201616715D0 (en) Therapeutic protein
ZA201608886B (en) Human cytolytic fusion proteins
TH1601000600A (th) โปรตีนการเชื่อมหลอมที่ใช้ในการรักษา
HK40007519A (en) Vaccines for use in treating various diseases and disorders